Evolus to Participate in Upcoming Leerink Partners and Barclays Investor Conferences

Rhea-AI Summary

Evolus, Inc. (EOLS) announces participation in upcoming investor conferences in March 2024. Management team to present at Leerink Partners Global Biopharma Conference and Barclays Global Healthcare Conference. Webcast available on Evolus website.

NEWPORT BEACH, Calif.--(BUSINESS WIRE)-- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will present at the following investor conferences in March.

Event: The Leerink Partners Global Biopharma Conference 2024
Date: Tuesday, March 12^th, 2024
Time: 10:00-10:30am ET

Event: The Barclays 26^th Annual Global Healthcare Conference
Date: Wednesday, March 13^th, 2024
Time: 8:00-8:25am ET

The fireside chats can be accessed on the Investor Relations page of the Evolus website here. A replay of the webcast will be available for 90 days after the date of the presentation.

About Evolus, Inc.

Evolus (Nasdaq: EOLS) is a global performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global, multi-product aesthetics company based on our flagship product, Jeuveau^® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Evolus is expanding its product portfolio having entered into a definitive agreement to be the exclusive U.S. distributor of Evolysse™, and the exclusive distributor in Europe of Estyme^®, a line of unique dermal fillers currently in late-stage development. Visit us at www.evolus.com, and follow us on LinkedIn, X, Instagram or Facebook.

Jeuveau^® and Nuceiva^® are registered trademarks of Evolus, Inc.
Evolysse™ is a trademark of Evolus, Inc.
Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240227499486/en/

Investors:

Nareg Sagherian, Vice President, Head of Global Investor Relations and Corporate Communications

Phone: (248) 202-9267

Email: ir@evolus.com

Media:

Email: media@evolus.com

Source: Evolus

FAQ

When will Evolus, Inc. (EOLS) participate in the Leerink Partners Global Biopharma Conference?

Evolus, Inc. (EOLS) will present at the Leerink Partners Global Biopharma Conference on Tuesday, March 12th, 2024.

Which event will Evolus, Inc. (EOLS) attend on Wednesday, March 13th, 2024?

Evolus, Inc. (EOLS) will participate in the Barclays 26th Annual Global Healthcare Conference on Wednesday, March 13th, 2024.

Where can investors access the fireside chats featuring Evolus, Inc. (EOLS) management team?

Investors can access the fireside chats on the Investor Relations page of the Evolus website.

How long will the replay of the webcast be available?

The replay of the webcast will be available for 90 days after the date of the presentation.